In short
Podcast Episode Notes: JPMorgan’s Sharp Reversal… And The Latest Entry To The Weight Loss Drug Battle - 5/20/24
Episode Overview This episode of CNBC's "Fast Money" discusses the recent performance of JPMorgan Chase shares and the implications of CEO Jamie Dimon's comments regarding stock buybacks and succession plans. Additionally, the episode explores the recent surge in shares of Hims & Hers after announcing their entry into the weight loss drug market.
Key Topics Discussed
- JPMorgan's Stock Performance
- Context: JPMorgan shares hit an all-time high but experienced a midday drop after CEO Jamie Dimon indicated he would not be buying back stock.
- Comments on Buybacks: Dimon's decision reflects a cautious stance amidst high valuations.
- Market Reactions:
- There was a significant trading volume of 175% above the average daily volume during the stock's reversal.
- Discussion centered around whether investors should follow Dimon’s lead and refrain from buying JPMorgan shares at current prices.
Key Arguments
- Valuation Concerns: Analysts mentioned JPMorgan's stock is trading at a premium (2.35 times tangible book value), suggesting it may be overvalued.
- Investment Strategy: Despite Dimon’s comments, some analysts argue that holding JPMorgan could still be a strong long-term investment due to its diversified operations and ongoing investments in technology.
- Implications of Dimon's Succession Comments
- Succession Planning: Concerns were raised about potential volatility and uncertainty surrounding Dimon's succession, given JPMorgan’s significant size ($4 trillion in assets).
- Investor Sentiment: Analysts suggested that the bank's cautious approach may bolster long-term confidence and stability.
- Hims & Hers and the Weight Loss Drug Market
- Surge in Shares: Hims & Hers shares jumped on the news of offering GLP-1 injections for weight loss, competing with larger pharmaceutical companies.
- Market Dynamics: The company plans to offer these medications at a lower price point compared to FDA-approved alternatives.
- Safety and Efficacy Concerns:
- Discussion included the FDA's warnings regarding compounded drugs and the importance of ensuring patient safety.
- Hims & Hers emphasized their quality assurance by collaborating with inspected compounding pharmacies.
Key Points
- Pricing Strategy: Prescriptions starting at $199 a month could attract customers amid current supply shortages for branded drugs.
- Future Outlook: Analysts questioned the sustainability of Hims & Hers' compounded offerings compared to branded options that may become available in the future.
- Broader Market Insights
- General Market Conditions: The discussion included insights into the overall market, highlighting that while the financial sector faces specific challenges, sectors such as technology, particularly related to AI, show potential for growth.
- Other Market Updates
- Target and Retail Sector: Target's decision to slash prices raised questions about its upcoming earnings report, with implications for market competition against Walmart.
- Investor Sentiment: The options market reflected mixed sentiments on Target, indicating uncertainty ahead of earnings.
Key Takeaways
- JPMorgan's Caution: Dimon’s comments on not buying back stock signal a cautious outlook on high valuations, but the bank's underlying strength may still appeal to investors.
- Hims & Hers Strategy: The company's entry into the weight loss drug market could provide a competitive edge, though safety and regulatory concerns remain paramount.
- Market Dynamics: The broader market remains volatile, driven by specific sectors' performances and investor sentiment regarding future earnings and economic indicators.
Conclusion This episode of "Fast Money" provided a thorough analysis of JPMorgan's recent stock performance and the implications of Dimon’s comments, as well as insights into Hims & Hers’ emerging role in the weight loss drug market. Investors are advised to consider both market dynamics and potential risks in their investment strategies amid the current economic climate.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:01Live from the Nasdaq marketside in the heart of New York City's Times Square. This is Fast money. Here's what's on tap tonight. From the diamond bottom to the diamond top, the J.P. Morgan CEO telling investors with prices where they are right now, he's not a buyer. Should his hold rating keep you from diving in? We'll debate that. Plus, off target, the retailer's stock struggling ahead of earnings, and now they're cutting prices on thousands of products in the store. Is this move a good sign or a warning shot ahead of results? And later, shares of him's and hers skyrocket on news. They are jumping on the obesity drug boom.
0:33But can they compete in a market where finding these GLP-1s and making them is a real challenge the company is set to weigh in. I'm Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Bono and Eisen, Dan Nathan, and Guy Adami. We start off with a sharp reversal in shares of JP Morgan today, the big bank hitting an all-time high early in the session, but then taking a tumble midday. The drop coming after CEO Jamie Dimon at the company's Investor Day said this. I think we're in a very good position to continue investing in our future, and we're not going to buy back stock now.
1:06Chair, buybacks have been as a big driver for stocks this year. Just take a look at the gains in Alphabet and Apple since those companies announced massive repurchase plans in their latest earnings report. But with stocks at all-time highs, the Nasdaq posting a record close today, the Dow sending a new intraday before pulling back. Have valuations gotten ahead of themselves? And if Jamie Dimon's not buying shares at J.P. Morgan at these levels, the question is, should you? Why are you laughing? Because you're in my head. It's like you read my mind. Like I'm thinking to myself, if Jamie Dimon is up by, why should you?
1:37And then you just said it. But the reversal today is very interesting. It was a lot of volume, 175 percent of the average daily volume. This reverse. Yeah, two more than two times. You're spot on with that. I'm glad you pointed it out. And we talk about price to tangible book, price to book. And he obviously watches the show from time to time because that is Zenith. J.P. Morgan got almost 2.35 times tangible book, almost two times book value, which historically is expensive. I mean, that's levels of traded at pre-financial crisis. So it's not an indictment of the bank. It's a great bank. It's just gotten to be a very expensive bank.
2:09So it's not me saying it. When you hear from him, you have to take notice. Well, I'm not sure I want to hear from J.P. Morgan. They're buying their stock back right now either, though. I mean, as an investor, I'm happy to. It doesn't mean I go out and sell J.P. Morgan because they're not buying. And I think there's an important difference. I also think that at times, Jamie, Jamie, Jamie Dimon, J.P. Morgan, he stepped in to buy his company when it has been, I think, absurdly cheap or at times when there's been places in the market to to inject confidence into the shares. I think about where companies, especially banks, are vilified for buying back shares.
2:43I mean, for him to get out there right now and say, I'm buying back stocks, I don't think Jamie Dimon is that concerned about public backlash. But I also think he's a guy who thinks about the big picture and thinks about every word he says. And I don't know that this is a place that he needs to say, I'm out there buying stock. So, again, we're talking about anywhere from a 60 to a 90 percent move in some of the biggest money center banks in the world, not just J.P. Morgan, which has actually underperformed some of those. Citi banks move 75 percent. You name it, a lot of these banks, European banks, some of the biggest banks in the world have had this move.
3:12Why are you buying back your own stock? It says you don't see anything else out there. And I don't I don't I don't think there's anything wrong with that. Yeah. So we're saying that or he is saying, you think, that it is fully valued. And I think that's a fair. So if you had a fresh dollar to work put to work in the markets today, would you be buying JP Morgan's stock? Or would you take a look at it and think, you know what, maybe I'm not going to do that because Jamie Dimon is not. Probably not. I mean, listen, you know, his strategist, his equity strategist has a forty two hundred dollar price target on the S &P 500.
3:38OK, so this stock, while it might have underperformed some of its money center peers of late, it's trading, a guy said, at a premium valuation price, a tangible book. And again, it was making new highs after that 6.5 % gap after its earnings lower on April 12th. It was down 10 % from then all-time highs in early April. Filled in the gap on what? I don't know. I mean, maybe some folks thought that they were going to kind of adjust this net interest margin a little higher. They obviously saved that for the investor day. So to me, I don't think it's a buy right here. Jamie's saying they're not buying it.
4:10They have other places to invest. The last thing I just say is that I think the stock obviously took that leg lower because of the succession comments. He's obviously been a Teflon sort of guy. He's basically dictated so many different things in the financial space over the last, call it, almost two decades or so. But this is a bank that has$4 trillion in assets. And when you think about succession, it probably goes in the hands of multiple. I could see two CEOs for this bank. When you think about how big it is and how divergent some of those businesses are. So that's something I think we're going to spend a lot of time talking about over the next couple of years.
4:42$4 trillion in assets and flush with capital, right? So I think this is a situation where you appreciate where this bank is coming from. Not to mention, Jamie Dimon has a long history of playing things on the conservative side, perhaps exorbitantly so. And so for me, given the fact that we've had the financial crisis, given the fact that we still can't get a read on inflation, we don't know where interest rates are going, I essentially want someone at the helm of the largest. And the reason why it trades with its premium valuations is because it's perceived to be the best bank approaching things with a cautious tone.
5:11Not to mention the fact that it's not as if they're sitting on this cash doing nothing with it. They continue to invest in technology. So for me to get behind someone that's saying, listen, we want long-term investment that's going to kind of bolster the stock over the long run. Sure, if you're trading it day to day, perhaps you're not jumping in today. But actually, this gives me even more confidence, you know, why I want this to be a core position in my portfolio and continue to invest going forward. I think key to this discussion also is the context in which this pronouncement is being made, and that is the macro context.
5:40And they talked about, first of all, they raised their net interest income forecast. But then they also said it's not going to be an even path. There's going to be tailwinds that turn into headwinds. And that's going to be when the Fed starts cutting rates. Eventually, whenever that happens, it will, in fact, be a headwind. And so in an environment like that, where you see the headwinds coming down the road, even if they might be a few quarters away, do you buy it at 1.8 times book? No, I don't think so. I mean, it's me. But I said this a while ago as well. I mean, it got more expensive on the way up.
6:08Obviously, it was just basically a market. It was a multiple expansion thing, which is fine. I mean, it works. But historically, that's sort of the deep end of the pool in terms of valuation for not only that stock, but for banks in general. With that said, I mean, I remember it was a Friday in February of 2016. The market was getting schmizeled. And about two o 'clock in the afternoon, J.P. Morgan, I think it was Jamie Dimon, announced that he personally was buying J.P. Morgan stock. I think this price was 58. Never saw that price again. I mean, he put his money where his mouth is. That's eight years ago.
6:38Now, this is not a reversal. I get it. But there's some subtleties here that makes you think, hmm, he saw something then, obviously. He sees something now. So if he was right then, it's probably smart to believe he's going to be right again. I guess we are right to think about every word he says. It's kind of, you know, Jamie Dimon is often like one rung below the Fed in terms of we think about every word he says. But I don't own J.P. Morgan so they can go buy back their stock. I own J.P. Morgan so they can go out and be in businesses that I think are a very diversified. This is the other part of the investor day.
7:06They talked about a business that's got such diversification. There's so many places where they are spreading that capital across. They also announced a buck 15 in a div, which is an excellent div. And look at the growth they've had in the dividend as a shareholder. I want to get paid. I want to get I want to get a dividend. So I guess I just look at it in the context of they told us that the credit card or NCOs were stabilizing. They told us that NIMS were better. What could I have wanted to hear after a 70 percent move in the stock? I mean, it's to me, it's what you're supposed to hear. If they say they're out there buying back their shares right now, it tells me there's not a lot of opportunity for their business.
7:41And to your point, they are spending on technology specifically. They raised their CapEx spend for the year. Part of that's going to be on, of course, AI, as everybody else is spending on AI. So they are investing in the future. But in terms of what this means for the markets, I mean, if we're thinking about a JP Morgan that trades at 1.8, fair. It could be fully valued. We're talking about markets that are at all-time highs, effectively, across the board. You talk about a utility sector that's trading at 1.7 on average in terms of price to book. So if you're thinking about J.P. Morgan versus a utility, I mean, put it in the context of the other valuations surrounding J.P.
8:15Morgan. And does J.P. Morgan start looking expensive or not as expensive? Well, you know, it's interesting that you mentioned the generative AI. Like, this is an industry that you could see taking tons of costs out, right, like using generative AI. So like if one of the first use cases is customer service and that ends up being something that could allow them, I know it sounds horrible, to replace, you know, thousands and thousands of workers with generative AI bots, then you're going to see a re-rating of some of these companies. If you see them make better loans, whether it be to individuals or just across their institutional, you know, this could go on and on and on where maybe all these banks get re-rated.
8:48It doesn't happen from here as a bank like this is at all-time highs. It's going to take years to figure that out. But again, a lot of folks have made the argument since post-crisis, I guess, that these are like utilities. They should trade at big discounts to the market and the like. And this is one story that actually could change. And it could change very quickly for the banks, but not right now. Not to mention back office and compliance. Staying out of the target of the FDIC, SEC, any of the other regulatory bodies. I think, listen, I think that tech spin is being allocated for a reason. We can talk about, you know, some of the chips or some of the other tech names.
9:20And, you know, they were kind of laughed at for the allocation to CapEx and allocating dollars that way. And it's paid off, at least in the short term. The last thing I'll say is, you know, kind of to Tim's point, I really don't want to see a CEO of the premier bank chasing short term performance, particularly at the all time highs. It's really about, you know, risk reward. If you're going to get an additional 3 % or 4 % kicker from a stock buyback versus being able to weather any potential storm that's coming down the pipe, I just think I'd prefer that cautious approach going forward. Real quick, I don't know what the – you're playing your phone?
9:55I mean, see, now people can see what goes on. What's the ringtone? You've got to tell us what's the ringtone. I think it was a concert. I mean, I saw a flash of video on it. No, don't be sorry. I mean, it happens. I mean, see, typically it usually happens to me, though. At least it's rated G. Anyway, let's move on. No, you can't pretend it doesn't happen. I mean, I was going to use my calculator. How about I turn this into just a natural TV moment? It's beautiful. As you were saying. Because we have to get Julian in here. I don't know the context. Was he asked the question? But I'd rather him say nothing at all than actually go out of his way to say.
10:27And again, I don't know what the context was, but it's just something to think about. Evercore ISI's top market forecaster thinks it is a wrong time to go bullish on stocks. Julian Emanuel is a firm's senior managing director. His S &P 500 price target is more than 10 percent below today's close. Julian, welcome. Is it harder and harder to stick by that forecast as markets go higher and higher? Well, by definition, it is. There's no question about it. But let's think about it, right? The first 10 minutes of this conversation, we've been focused on valuation. It is something that I would say in the course of years of me being with you all, we've talked about very, very little.
11:03But the point being that, you know, whether it's the consideration of earnings estimates that in our view are far too high, even though we had a good earnings quarter, but good earnings quarter was up five and a half percent. The market thinks the full year is ten and a half percent at twenty three and a half times earnings. You know, whether it's the premier investment bank bank stock in the world or it's the market in general, we just think this is a time to really think about risk reward here. And, you know, Goldilocks, despite the fact that we're either at two or one or zero cuts, continues to be priced very aggressively.
11:44Guy hates Goldilocks, by the way. Yeah, it makes me crazy. I'm giving Julian a pass because I love him. We just don't talk about it on Turkey Day. We'll talk about gold in a minute, so please. But, I mean, in terms of where we are right now and the risk-reward, one of the big risk events in the markets we've been talking about for weeks now is NVIDIA's earnings, which are coming up this week. Volatility is still extremely low right now in general for the markets. And so I'm wondering how you reconcile that and if you also think that, like many of the traders here, that NVIDIA is actually going to be sort of the thing that either sets this rally higher or sets us back.
12:18So it is one of the most unusual environments I think any of us have seen, because the amount of dispersion among stock returns is really record, which is why the index doesn't move. Think about today, right? We saw, you know, Jamie Dimon's bank sell off the way it did. At the same time, we had two plus billion shares in a number of meme stocks that, frankly, people don't know what the companies do and never even heard of them two weeks ago, buying and selling them. So it is a very unusual environment. And to us, in total, it says that risk in general is perhaps overpriced here. And we just it's not the end of the bull market in our view.
13:04And I think that's the message we got from from Jamie Dimon today. It's just a time to sort of let things settle in for a while. Julian, what's the deal with the VIX? I mean, we talk about the headwinds all the time. geopolitical stuff, blah, blah, blah, close below 12 on Friday. It's incredible. It goes to the dispersion. It also goes to the fact that the game has morphed for now into one day options, zero day and one day options. The one day VIX today traded in the fives, the lowest ever for the two years plus that it has been calculated. And from our point of view, when you think about it in the context of NVIDIA, it is true.
13:42That stock has been the market for the last year, and it's going to move. We're not sure which way, but the options market says it is going to move, and we expect the S &P to move with it. All right, Julian, the stock market hasn't worried too much about where yields are, right? And again, even when we started the year and there were six cuts that were priced, and now we have maybe one or two this year. Let's talk about inflation for a second here. So if the Fed keeps saying that, you know, 2%, they're going to stay the pat, you know, stay pat with higher for longer, that sort of thing. At some point, do you have to start figuring out what the cumulative gains have been since we got above that 2 % and kind of took off into 2022?
14:23Because, you know, do they have to actually keep yields much longer for, you know, higher for longer than a lot of folks think that they might have to do because of those cumulative gains over the last few years? I think that's some of the dialogue. And as much as we may not want to acknowledge it, there's no question about the fact the feedback loop from equity prices into confidence, into financial conditions is definitely there and has been for a number of years in central banking. And, you know, people want to compare this to 1995, the dawn of the Internet revolution. We're fully behind the idea that generative AI is going to be a game changer over the long term.
15:02But the difference between now and 1995, where you basically had a straight shot up for three years uninterrupted, is the Fed started cutting rates into the kind of economy we have now when inflation was already 2.1 percent versus 2.8 now. and stocks were trading 14 times, not 23 times. Julian, always good to see you. Thanks for coming by. Julian Emanuel, Evercore ISI. $47.50, you see that in the cards, Tim? It's possible. I tell you what, I think there are a lot of places where we are overextended. I give Julian and his team credit for also, you know, Julian at times has been very bullish on this market at times when it hasn't looked so great.
15:41And meanwhile, there's a strategist over there named Rich Ross who's been bullish the whole time, and he's been totally right. Right. So you have different dynamics here where I think and you mentioned the inflationary impact of where we are. I mean, when copper behaves like a meme stock, you have a strange dynamic for markets right now. Another record day for copper. That is inflationary, folks. It is Dr. Copper for a reason. It's woven throughout the economy. Commodity prices are moving higher. I don't think you get off that train, by the way. But inflation is an issue. We've got an earnings alert here on Palo Alto Network.
16:10Shares are falling in the after hours despite a beating at the top of the bottom line. It's a guidance that's getting them. So you can see Julie Borst has got all the details. Julia. That's right, Melissa. It does seem to be the guidance because the company's fiscal third quarter results beat on the top and bottom line. Revenues were just a tiny hair above expectations. And guidance for the fiscal fourth quarter was right in line with expectations despite that fiscal third quarter beat. CEO Nikesh Arora is saying on the call, which is still going on right now, that with AI, they do expect cyber attacks to come at a faster pace.
16:40He also said that their customers are responding well to their approach of cybersecurity consolidation, saying, quote, demand is robust. And my expectation is that we will continue to see it be that way over the next many quarters. But even with this afternoon stock declines, shares of Palo Alto Networks are still up 58 percent over the past 12 months. And Palo Alto Networks CEO Nikesh Arora will be joining our colleague Jim Cramer in an exclusive interview coming up on Mad Money. Melissa? Thank you. Julia Borsten for us. Guy, P-A-N-W. Yeah, I mean, it's all time high, not that it matters, but I think it was February of this year, 380-ish or so.
17:19It hasn't traded particularly well since. Problem, I think, is valuation. The quarter was fine. The guidance wasn't what people were looking for. Me, the question is, where do you get back in this thing? I think the recent low is like 268 or so. I mean, given sort of the market dynamics around now, I think 268 might be in the cards, Mills. They've had some recent misses, specifically on billings. And so there was a question about, I don't know, do you believe management? I think there's an issue still, given the guidance. Especially given where I think they sit in the middle of both the hardware, but more importantly on the software side of their business.
17:50And this is three straight billing quarters where they've had weakness. So I think this is kind of a problem. I am of the view, and if NVIDIA holds, and we just look at where the dominoes fall or are raised from NVIDIA, if that's the opposite of dominoes falling. But, I mean, software tends to follow semis. And semis closed today at all-time highs. Software has lagged. You're talking about Palo Alto. You're talking about Adobe. You're talking about the biggest and most successful software dinosaurs of the world. Not dinosaurs because I think they're yesterday's news, but because they're big. And they haven't really responded.
18:22This is disappointing. I think this is setting up for an opportunity. I think it's a bit of a cautionary tale what happens when you have a fully priced market and there isn't a guide forward. If we don't get that continued pull forward of earnings and are able to kind of present value that into today's terms, I think that's what might lead us lower. But as long as these things continue hitting on all fronts, and I do think NVIDIA will beat, but that will be the thing that cracks the market. Yeah, and it's worth noting. I mean, Tim kind of alluded to this. I mean, the genre of AI trade has been very narrow over the last year and a half.
18:51It's been basically the chip companies that, you know, predominantly NVIDIA, but then it's also been these large platform companies or these hyperscalers that have been able to benefit from that. And if you think about some of these SaaS companies, like, there's no doubt about it. Like, cyber is going to be a thing to combat a lot of stuff that's moving at much accelerated sort of paces. And so, again, the billings are not there. I think you're probably seeing some people stealing from Peter to pay Paul as it relates to their enterprise budgets right now. But ultimately, I think this is probably one that makes some sense.
19:21Coming up, Microsoft stepping up its AI ambitions, the tech giant's latest reveal ahead of its Build Developer Conference tomorrow. And the new class of PCs putting AI right at your fingertips. That's next. And a retail reduction from Target. The company slashing prices on thousands of items as inflation tightens consumers' wallets. What it could say about the competition and could a price war be on the horizon? Don't go anywhere. Fast Money is back in two. This is Fast Money with Melissa Lee right here on CNBC.
19:59Welcome back to Fast Money. Microsoft unveiling what it calls its smartest PCs ever. The lineup, a Surface Pro laptop and a Surface Pro tablet with Qualcomm chips that allow the devices to run AI features without draining battery life. The reveal coming just ahead of Microsoft's Build Conference, which officially kicks off tomorrow. CNBC's Steve Kovac is there, comes to us live from Redmond, Washington. Hey, Steve. Hey there, Mel. Yeah, so Microsoft announcing their new generation of PCs ahead of that Developers Conference kicking off tomorrow. They're calling them Copilot Plus PCs. Coming from manufacturers like Dell, HP, Samsung, and Microsoft itself, they come with a new PC chip from Qualcomm capable of processing Microsoft's AI tasks on the device.
20:42Whereas before, you needed an internet connection, and Microsoft says it expects this crop of AI PCs to convince people to upgrade their old devices and plans to sell 50 million of them by the end of the year. They start shipping next month. But the hardware really means nothing without AI capabilities. On top of that, on the software side, and Microsoft's co-pilot assistant is getting a number of upgrades on Windows, including automatic photo editing, real-time translation of languages, and a new feature they're calling Recall that can remember basically everything you've ever done on your PC.
21:16Windows will also incorporate OpenAI's latest version of ChatGPT, which was announced just last week. That's coming soon. And Microsoft also took several shots at Apple, claiming these AI PCs are faster and more capable than Apple's latest MacBook Air that launched just a few months ago. Microsoft also undercutting Apple on price, a couple hundred bucks cheaper than what Apple sells, depending on the model you get. Apple also doesn't yet have a generative AI tools like Copilot on Macs or iPhones. The message here from today's event for Microsoft, Apple's behind on AI, while Microsoft, which is considered the current leader for the tech, keeps pushing it forward, Melissa.
21:54All right, Steve, thank you. Steve Kovac joining us from Redmond, Washington. Is that the right thing? I mean, do you accept that, that Apple's behind, Microsoft is ahead, and here's proof of it? Yeah, I think they're clearly behind, but I just think the hardware aspect of this is just a marketing thing to give Microsoft, I guess, you know, some more time to kind of explain how far ahead they are. When you think about Apple's market share on the high end PC front and on tablets, you know, they're dwarfing, you know, on the high end, dwarfing what's going on. I think Apple will probably catch up pretty quickly.
Read the full transcript
22:25They're not talking about really on device. It's going to be cloud based AI functionality that probably happens in the fall. So right now, a lot of people are using their fancy iPhones and they're using apps like Perplexity and they're getting a lot of this stuff. Once it gets integrated across their productivity suites and the like, that's a different story. But that's a 2025 thing. I think it's been well flagged that Apple is not the one in there innovating on this stuff. And I don't think that really matters when you have that installed base and when you have that software business and you have that brand identity.
22:52It's also noted that, by the way, from Mark's perspective, Apple significantly outperformed Microsoft now over the last month. Microsoft's done nothing. It's underperformed the S &P by two and a half percent. And all we do is talk about how far in front Microsoft is. So the valuation is not terribly attractive at this point. And I'm not saying Apple's is either. I'm just telling you, the market is telling you we'd rather own Apple over Microsoft. Oddly enough, we're talking about Apple potentially chasing Microsoft. It seems that Microsoft is trying to reinvent some of Apple's cycle performance, right?
23:21So you have this PC, and they were a bit subtle with what they said, but there is some on-PC features in terms of the AI situation. So we talked about Palo Alto Networks. We talk about cybersecurity. This will this will help there. And I think this will, in fact, compel users to perhaps push that cycle forward. The question is, you know, these aren't iPhones. These are PCs. So you're talking about a three to five year cycle versus maybe a one or two year cycle. So after you've made the purchase, then what? But I do think this gives them perhaps, you know, two to three years of runway to come up with the next thing.
23:52A lot of fine shows on CNBC. You would agree. So many. Nine a.m., the squawk on the street. I don't think you can remember the fine shows on CNBC. No, I could rattle him off if need be. But JC was on this morning. He said this would be the. Yeah, JC. The biggest refresh cycle in PC history. And he might be right. But to Tim's point, you better hope it is because at 33 times next year's numbers, Microsoft is expensive in this environment. If you're a business, are you going to opt to buy this newest, latest PC, which I'm guessing is going to be more expensive, on the bet that you're going to also buy a co-pilot subscription at however much,$30 a head per month?
24:28No way. Is that the bet that we're making in terms of believing what Microsoft is unveiling today? It's not a CapEx bet that people are making on the enterprise side for their people. I mean, we hear what's going on the enterprise side, and that's not where they're making it. There's a lot more Fast Money to come. Here's what's coming up next. Missing the markup. Target slashing prices on thousands of items as consumers feel the inflation pinch. what the changes could say about the competition, and how options traders are playing the move ahead of earnings. Plus, HIMS getting in on the SLIMS, the digital pharmacy company is getting in on the weight loss drug craze, and shares are packing on the gains.
25:11But can it keep the wait on? You're watching Fast Money, live from the NASDAQ market side in Times Square. We're back right after this.
25:29Welcome back to Fast Money Stocks. Closing mixed to kick off the week. The Dow dropping nearly 200 points after hitting an intraday record early in the session. It is back under the 40 ,000 level. The S &P notching a small gain and the Nasdaq leading the gains up more than half a percent, closing at a record high. Some more after hours action shares a zoom off its worst of the after hours after reporting results. The company beating at the top and the bottom line, but guidance coming in a bit light. Shares of Norwegian Cruise Line jumping nearly 8 % during the session. The company raising its full-year profit forecast as vacation demand and ticket prices continue to climb.
26:01And more metal magic. Gold settling at another record high, while copper hitting a fresh all-time high as well. And silver reaching its highest level in more than a decade. Now, I think that we don't talk about Dan Zebra nearly as much as we should be. And with Zoom reporting results down 1.25 % in the after hours, we've got to go to you on that. Well, it's not Guy's clam, but Zebra has some stealthy folks in there. Well, here's the problem with Zoom right now. Customer growth is just anemic, and that's been true for the last few quarters or so. It trades 13 times. The company that's growing earnings and sales at low single digits here, 40 % of their market cap is in cash and has 78 % gross margins.
26:40Why is this the Z in Zebra? The way I play the game, Sandy, I look for names that have been beaten up and have the potential to get taken out. I'm talking to Sandy right now. Because he knows that we have issues. And so I think it gets taken out eventually. I think when you have that sort of framework, that sort of balance sheet, that sort of customer base and that cheapness, to me, it sounds interesting. Play the game, the win. I mean, you know, the acronym game, the acronym game. Yeah. And if you look at my clam and how you doing pretty well, they're out of Kimo Sabe. Take a look at Agnico Eagle.
27:09Now, so let's get back into the market stuff. A in the clam is AEM. And this stock has been on fire as the entire space has been. And thank you for mentioning silver because finally that's on its horse. And the silver stocks are doing well. I'll give copper to Tim because he's been on it. But Freeport-McMoran is a whisper away from making, I think, now 16-year highs or something. Is copper in your – it's not in your acronym, though. It has been, but, you know, look, I mean – It has been in the past, but not this year. Like, if we want to talk about the blicep, we can. We can go name by name. And I stand by those names, especially the international and iDevo.
27:44I will say I think copper is a little euphoric here. But if you are pricing copper companies like Freeport or Southern Copper or Antofagasta at five bucks a pound in copper, they should go up two and a half times from here. Coming up, the skinny on hims and hers. The wellness stock soaring on news that will offer GLP-1 medications, but not the big name drugs like Wagobi and Azempic. We'll dive into whether the company's plan can live up to investor hype. That's next. Plus, target shares tripping up after announcing sweeping price cuts. Is this a sign that Wednesday's earnings could be ugly? A closer look at some surprising sentiment in the options market.
28:19That's next. Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.
28:38Welcome back to Fast Money. Target shares dropping after the company announced it will lower prices on more than 5 ,000 food and household essentials like diapers and paper towels. The cuts coming as a retailer gears up to report earnings before the bell on Wednesday. And as its main competitor, Walmart sits very near all time highs. Are these cuts a sign that Target is trying to regain market share that earnings could actually be ugly? It is curious timing. Just a couple of days beforehand, they're saying we're going to cut prices on all sorts of everyday prices, mostly groceries ahead of its earnings.
29:09One more reported on May 16th. This is my again. This is just me sort of reading the tea leaves. They saw Target saw their inventories were down two point seven percent year over year against sales growth of almost six percent. They said, OMG, we're not going to be able to do that. I think they have an inventory problem again. They're trying to get ahead of something ahead of earnings. I don't think it augurs particularly well. So that's just me trying to figure things out. I think they're going to have a margin problem. I think they have an inventory problem. So reading a note here by Jeffries, I mean, their argument is this is actually good for consumers and Target.
29:38that actually gives them a chance to go back in there, get some market share. They have efficiency offsets. I think that's an interesting theory. It doesn't necessarily mean it's a five-alarm fire. It means this is a company that may be actually looking to take on. I mean, they've lost a lot of market share, and it's a case where we know what's going on with the segment mix and what's not been working for them and working for Walmart. I kind of like the move. If we dissect how Walmart has been gaining share, especially among higher income households, it's because the grocery prices are very low.
30:08So people go in for groceries, they buy general merchandise. Is Target able to replicate that if they cut prices on groceries when they're general merchandise prices? It's a different mix. It's just a different kind of mix of general merchandise at a higher price point. General merchandising and clothing and, you know, home decor type of stuff. You know, listen, I'm going to try to find the positive side of the coin. It's a bit tough for me. I think if they were making the promotionals in that business, which is where their margins are the highest and really what their core business model is, I think that would be the five alarm signal.
30:36I'm willing to buy in a half of Tim's argument in terms of this being good for Target and, sorry, Tim's quoted argument, good for Target and good for the consumer. I think it's good for the consumer. I mean, competition technically always is. However, I do think this is them acknowledging the fact that their numbers are going to look dire compared to Walmart's. And the last thing I'll say is I was looking at that Ford spread. It's about 10 turns, 27 to 17, which starts to look attractive. But then you really drill down into what's going on in terms of the promotions. And we've seen this story play out before when they got the inventories wrong, they got the business mix wrong.
31:08And at this time, I think they're just going to really have to struggle to gain back market share from Walmart, which has already become, you know, a go to sticky type of customer. Cheap for a reason, he's saying Target is. You know, it's hard to figure this stuff out. Like a week ago, we were trying to figure out that headline about Walmart. They were making some like like cost cuts. They were kind of headcount reduction, that sort of thing. You say, well, if they're doing that two days before their earnings, what are we going to expect? So this is a tough one. you can never really figure out why companies make these announcements when they do.
31:36They could have waited for earnings. But again, you know, if inventories are really tight here, this is something that if they don't have those offsets for efficiencies, then this should weigh on margins. And what does that say about their ability, you know what I mean, to kind of keep the market share that they have if Walmart's really eating their lunch? Yep. Well, the options market is actually getting positive on target late in the day. Mike Ho joins us now for a closer look at the action. Hey, Mike. Hi there. Yeah, you really hit on it because actually right after this cost-cutting news came out, initially the flow was actually quite bearish.
32:06When we saw this morning, we saw well over average daily put volume. But by the end of the day, we had about 1.75 times the average daily options volume overall. But calls did outpace puts. And the busiest calls were the June 165 calls. We saw about 1 ,800 of those trading for about$3.89 a contract. Buyers of those calls are obviously betting that targets implied move, which right now is about 7 % by the end of the week, could actually be to the upside. They're risking about 2.5 % of the stock price to make a bet that it could recover almost to the levels that it saw a week ago. And I think that expresses some of the uncertainty around the timing of this announcement, which obviously, as Dan just pointed out, could trim margins somewhat, which hit, I think, a low of about 2.8 % about two years ago.
32:48All right. Mike, thanks. Mike Coe. Coming up, the skinny on HIMSS shares of digital pharmacy startup HIMSS and HERS soaring after announcing it's adding weight loss medications to its platform. We'll talk to a company executive who'll join us next to discuss all the details. And throughout May, CNBC is celebrating Asian American, Native Hawaiian, and Pacific Islander heritage. Here's our own Deirdre Bosa.
33:13Asian Americans in the Workplace report a significantly higher frequency of receiving negative feedback at nearly twice the rate of other ethnic groups. That's according to a study by the Boston Consulting Group, which also found only 19 percent of respondents believed they were getting a fair shot to reach upper management. For Asian-American Native Hawaiian Pacific Islander Heritage Month, I'm Georgia Bosa.
33:45Welcome back to Fast Money. Shares of HIMS and HER soaring 27 percent today after announcing it will offer a compounded GLP-1 injection that patients can access via providers on its platform. The drugs are not FDA-tested or recommended, but allowed because of current supply shortages. HIMSS and HERS following behind providers like Roe in offering compounded formulas. Prescriptions start at$199 a month, far below the list prices of FDA-approved drugs currently offered by Lillian Novo. But how does a new offering really size up against existing competition? Let's ask HIMSS and HERS Senior Vice President of Weight Management, Dr.
34:19Craig Premack. Dr. Premack, great to have you with us. Thanks for joining us. Thank you. The price obviously is much, much lower. What do you tell patients, though, about safety, particularly when the FDA has issued warnings about the safety of compounded semaglutide? We spent a lot of time at Hims and Hers trying to find a pharmacy that would able to give us both quality. And so the pharmacy was very vetted. They went over 400 different observations. It is a 403B compounding facility, which is inspected by the FDA. And we had to find not only quality, but also affordability and supply. Sure. There's two types, 503A and 503B, 503B being FDA licensed, FDA inspected, and so on.
35:08But still, they are, I would assume, making a compounded version of semaglutide that's either semaglutide acetate or semaglutide sodium. And the FDA in its warning in January has said that it has no basis. The FDA is not aware of any basis for compounding a drug using semaglutide salts, sodium, that would meet federal requirements. Do you tell patients that this is just as safe as a brand name drug? So what are patients getting into at this point? I understand that it's going to be huge for the business of hims and hers, but how do you ensure that the patients are aware of what the risks may Yeah, great question.
35:44And the first thing is we are not compounding a salt version. We are compounding the base version. We are not using B12, which a lot of people have used also. This is CGMP qualified and as close to the base compound as you can get. So close to the base compound, meaning what? I mean, is it semaglutide acetate then, or is it something else that I'm not aware of? We call it semaglutide base. So it is not a salt form at all. Oh, I see. Okay. What is the trajectory? Do you think you work not only with hims and hers, but also various weight management centers in the Phoenix area? What do you think the trajectory is as prices start coming down?
36:20I'm already with coupons. You can get some of these brand name drugs for$500 a month, which is very different from the list price. And eventually there will be generics. Granted, that's sometime in the future. How do you see this in terms of it being a sustainable part of him's and hers business? It's not just semaglutide. So we are offering a complete weight loss solution. So we do have oral medications. We have compounded medications. And right now, using the numbers that you do, people cannot go to the local pharmacies. I'm in Arizona, especially in Arizona. And there's a three or four week wait just to get them even at those prices, as the prices seem to come down.
36:56And more and more Americans are able to take care of their health through weight loss as a comprehensive fashion, I think we will be able to match our supply to what they need. Do you have any sense of who the incremental customers at this point are? These people who have prescriptions because of cardiac needs or actually they're obese? Because I've been on some of these telehealth sites as part of my documentary, and you can very easily, without having the proper BMI, get compounded semaglutide from a pharmacy. We use what we call FDA criteria. So your BMI has to be over 30 or 27 with several weight-related factors if we're using compound disemaglutide.
37:41And also, you have to be a candidate. So you don't have any other of the problems that you could potentially have that would make you a non-candidate, which is why we also offer the oral medicines also. So if you're not a candidate for one, you will be a candidate for a comprehensive approach to all of them. What are the oral medicines that you're offering? We offer metformin, topiramate, and then bupropion and also naltrexone and compounded sometimes with B12, depending on the patient and what their needs are. So we're able to personalize the offerings. Dr. Premack, thanks so much for joining us.
38:16Appreciate it. Thank you. Craig Premack of HIMS and HERS. The concern among the analysts that, you know, in terms of the notes that I've read today, is that this is not necessarily a sustainable part in terms of this particular contribution to him's and hers revenue. Compounded versus branded. Exactly. Yeah. And that once the branded suppliers actually have the ability. Generic, et cetera. Compounded is going to. Yeah. I mean, based upon what Lilly has done, it's not surprising, especially with a smaller market cap company, that you saw this kind of a reaction. But asking important questions like the ones you just asked and the health dynamics that I think are still very unknown, in reality, offers probably a very different outcome.
39:00How much runway is low left before the market realizes it's unsustainable? And this is actually, you know, congratulations, because out of the dozens, if not hundreds of SPACs that came out, this is one that's actually seemingly succeeding now, I think with 2020 or so. So I actually say stay with the name here. Yeah, I'll just say this. I mean, there's so few ways to actually play this right now. That's probably why you get to sort of move on that sort of market cap. Coming up, Wall Street binging on Netflix. Why analysts are giving the thumbs up on this streamer and if shares continue their recent run up.
39:27That is next. More Fast Money in two.
39:41Welcome back to Fast Money. Shares of Netflix climbing more than 3 % today and closing at its highest level since November 2021. The move coming after a bullish call from Wedbush, which reiterated its outperform rating, raised its price target to 725. That's 13 % upside from here. Analysts there are saying the company has won the streaming wars and that it will reap benefits from both its password crackdown and its ad tier. Bonnan, what do you think? Agree? I tend to agree. I definitely think they've won the streaming wars. We've just seen a lot of bodies strewn in that war. I really just wonder how much upside there really is from here.
40:12So I would say I tend to agree with a relatively quick hook. I'd probably look to buy some puts or something given volatility being so low. The analyst says the competitors will flail trying to replicate Netflix's business model at this point. I think what they're doing with this live stuff, and they're just kind of scratching the surface, they're going to have this big Logan Paul, Mike Tyson fight. Oh, you got it this time. Yeah, I got the name. But they're also doing a lot of stuff. They're doing this really interesting thing with David Chang. I just think there's a lot of stuff. And then obviously getting into sports rights or whatever, they do that properly.
40:40So to me, I think, again, pullbacks like the one we just had after that earnings, they kind of got bought. I mean, they have two NFL games coming Christmas. Christmas Day? So I've got to watch it on the Netflix. Oh, the Giants playing Thanksgiving. Well, think of the ads that can be sold surrounding that game. You think so? You're live. You tend to build your Christmas Day around football, right? Hold on. Let's look at the schedule first. Real quick. I mean, they're actually, again, they got expensive. Then I think the numbers for next year, they're$23 almost. So now at 27 times, that 690 level from October 21 is actually in the crosshair.
41:20So I think, as Tom Rogers would say, you stay with this. So much for not liking the standards in which they're going to start reporting some of their data and some of their – I mean, no one cares. At the end of the day, when you have this kind of free cash flow and the stocks now rallied almost 20 percent in 12 sessions or so since that disappointing announcement, it wasn't. Up next, final trades.
41:52Do not miss the CNBC Financial Advisor Summit on Wednesday, where our very own Tim Seymour is joining the panelists. How about that? And the QR code to register or visit CNBCevents.com slash FA. Time now for the final trade. Around the horn we go, Tim. And I'm going to be, I think, with Savita and me. And with Melissa and Savita. So, Melko. China's tailed off a little bit, but I think the recovery in Macau just beginning, I think Melko is the way to play it. Bono in. JP Morgan. Listen, I think there's a history of being conservative there. They're flush with cash. I'd like for an entry point. Is that Nathan?
42:25Yeah, the Z and Zebra. That's fine. That's going to be a feisty set, Tim. I look forward to watching that. Yes. By the way, Chris Kreider, huge Fast Money fan. Shout out to Kreider. I mean, that was historic. It's ridiculous. Wednesday night, baby. We'll be there. Do you have a final trade? Great. All right. Thank you for watching Fast Money. See you back here tomorrow at 5. Mad Money with Jim Kramer starts right now.
42:52and do not reflect the opinions of CNBC, NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.
43:22To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.
From the publisher
Shares of JPMorgan losing steam in the session after CEO Jamie Dimon’s comments on owning the bank, and his own succession plans. Where the financial heavyweight is heading next. Plus Telehealth provider Hims & Hers surging after announcing it will offer GLP-1 injections. How they’re hoping to tip the scales in the obesity drug wars.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
